← Back to headlines
Neurocrine to Acquire Soleno, Securing Drug for Relentless Hunger Disorder
Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, thereby obtaining a drug designed to treat a relentless hunger disorder.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
